|
Transgene is a fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases. Our expertise covers all stages of product development, from research to the manufacture of clinical batches, and the conducting of clinical trials.
Five products are currently under clinical development, three in phase II and two in phase I. A partnership agreement has been signed with Roche for the further development of one of these products, TG4001/R3484, for the treatment of precancerous cervical lesions caused by the HPV virus. >>> READ MORE |
December 1, 2009
Transgene Receives FDA Fast Track Status for its Targeted Immunotherapy product TG4010... >>> READ MORE
November 4, 2009
Transgene: First Patient enrolled in Phase I Trial of TG4023... >>> READ MORE
October 19, 2009
Transgene: Cash position of €72.9 million as of September 30, 2009... >>> READ MORE
|
Products
Cancers
 Infectious diseases
  |
PUBLICATIONS
|